Pacifica Partners Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ

Pacifica Partners Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 42.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,310 shares of the company’s stock after selling 16,629 shares during the period. Johnson & Johnson comprises about 2.1% of Pacifica Partners Inc.’s holdings, making the stock its 18th largest holding. Pacifica Partners Inc.’s holdings in Johnson & Johnson were worth $4,626,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $26,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter valued at approximately $28,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $41,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $235.03 on Wednesday. The stock has a market capitalization of $566.09 billion, a P/E ratio of 21.27, a PEG ratio of 2.32 and a beta of 0.34. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $236.15 and a two-hundred day simple moving average of $209.61.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HSBC increased their target price on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Citigroup raised their price objective on Johnson & Johnson from $250.00 to $274.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. Finally, Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 1 intravesical delivery of erdafitinib in non‑muscle invasive bladder cancer reported high (≈89%) response rates and durable complete responses with a favorable safety profile — a meaningful clinical readout that could expand J&J’s oncology opportunity if confirmed in later trials. Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate
• Positive Sentiment: FDA cleared the TECNIS PureSee intraocular lens (extended depth‑of‑focus option) — expands J&J’s cataract/vision portfolio and supports procedure revenue growth in ophthalmology. Device approvals tend to drive steady, low‑volatility revenue additions. Johnson & Johnson Targets Procedure Growth With Bladder Cancer And Vision Advances
• Positive Sentiment: Company is pursuing oncology expansion with new trials and delivery technologies, underscoring management’s focus on growing the oncology franchise over time. This supports longer‑term sales and pipeline value. Johnson And Johnson (NYSE:JNJ) Targets Oncology Growth Through New Trial Russell 1000
• Positive Sentiment: Collaboration/clinical partnering moves (e.g., work with Protagonist) aim to broaden immunology/dermatology and compete with established products like Skyrizi — potential upside if programs advance. Protagonist Partners With Johnson & Johnson To Compete With AbbVie’s Skyrizi
• Neutral Sentiment: Technically, JNJ has traded above its 50‑ and 200‑day moving averages for months, which many investors view as bullish momentum — may support demand absent new negatives. J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
• Neutral Sentiment: Analyst/ broker commentary and ratings pieces are circulating; these can influence intraday flows but don’t change fundamentals unless accompanied by guidance or material news. Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet
• Neutral Sentiment: Former J&J oncology executive Craig Tendler moving to TuHURA is being reported; as he is already a former head, immediate operational impact at J&J appears limited. Craig Tendler, M.D., JNJ’s Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience’s VISTA Program in AML and other Blood Related Cancers
• Negative Sentiment: Analyst pieces also flag ongoing patent and legal risks (historical and potential future litigation) that remain a valuation overhang and could spur downside if developments accelerate. J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.